Image-guided tumor surgery: The emerging role of nanotechnology.
Nicholas E WojtynekAaron M MohsPublished in: Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology (2020)
Surgical resection is a mainstay treatment for solid tumors. Yet, methods to distinguish malignant from healthy tissue are primarily limited to tactile and visual cues as well as the surgeon's experience. As a result, there is a possibility that a positive surgical margin (PSM) or the presence of residual tumor left behind after resection may occur. It is well-documented that PSMs can negatively impact treatment outcomes and survival, as well as pose an economic burden. Therefore, surgical tumor imaging techniques have emerged as a promising method to decrease PSM rates. Nanoparticles (NPs) have unique characteristics to serve as optical contrast agents during image-guided surgery (IGS). Recently, there has been tremendous growth in the volume and types of NPs used for IGS, including clinical trials. Herein, we describe the most recent contributions of nanotechnology for surgical tumor identification. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Implantable Materials and Surgical Technologies > Nanoscale Tools and Techniques in Surgery Diagnostic Tools > in vivo Nanodiagnostics and Imaging.
Keyphrases
- minimally invasive
- coronary artery bypass
- high resolution
- drug discovery
- clinical trial
- magnetic resonance
- randomized controlled trial
- magnetic resonance imaging
- robot assisted
- surgical site infection
- prostate cancer
- computed tomography
- drug delivery
- fluorescence imaging
- atrial fibrillation
- contrast enhanced
- open label
- study protocol